<DOC>
	<DOCNO>NCT00004050</DOCNO>
	<brief_summary>RATIONALE : Inserting gene interleukin-2 person 's cancer cell may improve body 's ability fight cancer . Using Leuvectin deliver gene may effective treatment prostate cancer . PURPOSE : Phase II trial study effectiveness Leuvectin follow surgery treating patient stage II stage III prostate cancer .</brief_summary>
	<brief_title>Leuvectin Followed By Surgery Treating Patients With Stage II Stage III Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Assess toxicity tolerability neoadjuvant Leuvectin patient stage II III prostate cancer . - Evaluate efficacy regimen prevent delay manifestation disease progression demonstrate biochemical failure clinical recurrence patient population . OUTLINE : This multicenter study . Patients receive Leuvectin intraprostatically 10-30 second ultrasound guidance day 0 follow second injection day 4 7 . Between day 8 14 , patient undergo retropubic prostatectomy . All patient follow 2 month . Patients PSA great 0.2 ng/mL follow 4 month 6 month , every 3 month 12 month , every 6 month 3.5 year absence disease progression biochemical failure . ACTUAL ACCRUAL : 13 patient accrue study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm stage II III organ confine prostate cancer Resectable disease ( candidate retropubic prostatectomy ) Gleason score least 6 Prostate specific antigen value ( PSA ) least 5 ng/mL No significant central nervous system ( CNS ) disease PATIENT CHARACTERISTICS : Age 18 Performance status Karnofsky 80100 % Eastern Cooperative Oncology Group ( ECOG ) 01 Life expectancy Not specify Hematopoietic White blood cell count ( WBC ) great 3,000/mm^3 Platelet count great 100,000/mm^3 Hemoglobin great 9.0 g/dL Hepatic Bilirubin normal ; serum glutamic oxaloacetic transaminase ( SGOT ) , serum glutamicpyruvic transaminase ( SGPT ) less 3 time upper limit normal Prothrombin time ( PT ) /partial thromboplastin time ( PTT ) normal Albumin great 3.0 g/dL Hepatitis B surface antigen negative Renal Creatinine normal Cardiovascular No uncontrolled hypertension No significant cardiovascular disease No history ventricular dysfunction arrhythmia No congestive heart failure No symptom coronary artery disease No prior myocardial infarction Other No active autoimmune disease No active infection require parenteral antibiotic HIV negative No significant psychiatric disorder would preclude compliance No malignancy within past 5 year except curatively treat basal squamous cell skin cancer No diabetes mellitus Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No prior chemotherapy prostate cancer At least 5 year since prior chemotherapy Endocrine therapy No prior glucocorticoid prostate cancer At least 5 year since prior glucocorticoid Radiotherapy No prior radiotherapy prostate cancer At least 5 year since prior radiotherapy Surgery See Disease Characteristics At least 4 week since prior intrathoracic intrabdominal surgery At least 2 week since major surgery Other At least 10 day since prior anticoagulant nonsteroidal antiinflammatory agent No neoadjuvant concurrent anticancer drug No concurrent immunosuppressive drug No concurrent experimental therapy No concurrent parenteral antibiotic</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>stage IIB prostate cancer</keyword>
	<keyword>stage IIA prostate cancer</keyword>
	<keyword>stage III prostate cancer</keyword>
</DOC>